Abstract:Recent advances in cancer immunotherapy, particularly the success of immune checkpoint inhibitors, have reignited interest in targeted monoclonal antibodies for immunotherapy. Antibody therapies aim to minimize on-target, off-tumor toxicity by targeting antigens overexpressed on tumor cells but not on healthy cells. Despite considerable efforts, some therapeutic antibodies have been linked to dose-limiting side effects. Our hypothesis suggests that the efficacy of IgG leads to a lower target expression threshold for tumor cell killing, contributing to these side effects. Earlier, therapeutic IgG antibodies were reformatted into the IgA isotype. Unlike IgG, which primarily engages Fc gamma receptors (FcγR) to induce antibody-dependent cellular cytotoxicity (ADCC) by NK cells and antibody-dependent cellular phagocytosis (ADCP) by monocytes/macrophages, IgA antibodies activate neutrophils through the Fc alpha receptor I (CD89, FcαRI). In previous studies, it appeared that IgA may require a higher target expression threshold for effective killing, and we aimed to investigate this in our current study. Moreover, we investigated how blocking the myeloid checkpoint CD47/SIRPα axis affect the target expression threshold. Using a tetracycline-inducible expression system, we regulated target expression in different cell lines. Our findings from ADCC assays indicate that IgA-mediated PMN ADCC requires a higher antigen expression level than IgG-mediated PBMC ADCC. Furthermore, blocking CD47 enhanced IgA-mediated ADCC, lowering the antigen threshold. Validated in two in vivo models, our results show that IgA significantly reduces tumor growth in high-antigen-expressing tumors without affecting low-antigen-expressing healthy tissues. This suggests IgA-based immunotherapy could potentially minimize on-target, off-tumor side effects, improving treatment efficacy and patient safety.

Neutrophils as immune effector cells in antibody therapy in cancer

Therapeutic exploitation of neutrophils to fight cancer

The Neutrophil: The Underdog That Packs a Punch in the Fight against Cancer

Neutrophils in cancer: from biology to therapy

Rational targeting of immunosuppressive neutrophils in cancer

Neutrophils in Cancer immunotherapy: friends or foes?

Neutrophils' dual role in cancer: from tumor progression to immunotherapeutic potential

Human tumor-associated macrophages and neutrophils regulate anti-tumor antibody efficacy through lethal and sublethal trogocytosis

Tumor-associated neutrophils and neutrophil-targeted cancer therapies

A neutrophil response linked to tumor control in immunotherapy

Targeting and Exploitation of Tumor-Associated Neutrophils to Enhance Immunotherapy and Drug Delivery for Cancer Treatment

Targeting myeloid cells with bispecific antibodies as novel immunotherapies of cancer

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Neutrophils in cancer: dual roles through intercellular interactions

Neutrophils in Cancer and Potential Therapeutic Strategies Using Neutrophil-Derived Exosomes

The tumor cell killing capacity of head and neck cancer patient-derived neutrophils depends on tumor stage, gender and the antibody isotype

Cancer therapy with antibodies

Targeting neutrophils: Mechanism and advances in cancer therapy

Role of Neutrophils on Cancer Cells and Other Immune Cells in the Tumor Microenvironment

Neutrophils in the tumor microenvironment: role in tumor progression and potential targeted therapeutic strategy

Neutrophil diversity and plasticity in tumour progression and therapy